Seagen

2 trends tracked about this subject — the full history, oldest to newest below.

↓ Cooling Business 🔮 fades ✓

Pfizer’s first drug candidate from its Seagen acquisition, sigvotatug vedotin, failed to meet primary endpoints in a Phase 3 nonsquamous NSCLC trial.

5 sources 5 articles v 3 1d ago

▲ Peaking Business 🔮 fades ✓

Pfizer’s experimental lung cancer drug sigvotatug vedotin has failed to meet its primary objective in a late-stage clinical trial.

5 sources 5 articles v 3 1d ago